{"id":24031,"date":"2022-05-13T14:40:14","date_gmt":"2022-05-13T13:40:14","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=24031"},"modified":"2022-05-13T14:40:19","modified_gmt":"2022-05-13T13:40:19","slug":"spero-therapeutics-announces-new-strategic-direction-focusing-on-advancing-promising-clinical-stage-pipeline","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/spero-therapeutics-announces-new-strategic-direction-focusing-on-advancing-promising-clinical-stage-pipeline\/","title":{"rendered":"Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline"},"content":{"rendered":"\n

Article published on Spero Therapeutics website<\/a> on May 03, 2022<\/p>\n\n\n\n

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it will immediately defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting (LCM) with the U.S. Food and Drug Administration (FDA) regarding Spero\u2019s New Drug Application (NDA) for tebipenem HBr. Although the review is still ongoing and the FDA has not yet made any final determination regarding approvability, the discussion suggested that the data package may be insufficient to support approval during this review cycle, as described below.<\/p>\n\n\n\n

In connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operating costs and reallocate resources towards the clinical development programs of SPR720 and SPR206, while continuing engagement with the FDA on the appropriate path forward for tebipenem HBr. Based on the anticipated cost-savings of this restructuring and other assumptions, Spero anticipates it will be able to fund its planned operating expenses and capital expenditure requirements pursuant to the priorities of its strategic refocusing through late 2023.<\/p>\n\n\n\n

\u201cWe are disappointed that the FDA has identified substantive review issues, and we strongly believe that tebipenem HBr would offer healthcare providers, payers and patients an important oral antibiotic alternative to IV treatment for cUTI for patients with limited oral treatment options,\u201d said\u00a0Ankit Mahadevia, M.D., Chief Executive Officer of\u00a0Spero Therapeutics. \u201cAfter careful consideration, and in light of the current FDA position, we have made the strategic decision to transition Spero\u2019s focus and resources to supporting the clinical development of our promising clinical-stage pipeline, including SPR720, aimed at treating non-tuberculous mycobacterial lung disease, and SPR206, aimed at treating MDR gram-negative bacterial infections. <\/p>\n\n\n\n

Further, we will continue to engage with the FDA on the appropriate path forward for tebipenem HBr. As a result, Spero will immediately refrain from investment in near-term commercialization activities for tebipenem HBr, and instead we will restructure our business to appropriately staff our new focus going forward. We believe these actions will help preserve the ongoing viability of tebipenem HBr\u2019s development program, enabling either eventual commercialization by Spero, or commercialization through potential partnership or other opportunities.\u201d<\/p>\n\n\n\n

Dr. Mahadevia continued, \u201cWhile this decision was difficult, we believe it is in the best interest of the company and its shareholders. The need for antibiotic resistance solutions is more pressing than ever before, and both SPR720 and SPR206 are in clinical development stages and have shown promising results to date. SPR720\u2019s Phase 2 clinical hold was recently lifted, enabling its continued development as an oral therapy for non-tuberculosis mycobacterial infection, a debilitating, chronic disease. We are also very pleased with the ongoing development of SPR206 as a treatment for MDR gram-negative lung infections. Finally, we believe in the long-term potential of tebipenem HBr for patients with cUTI and look forward to engaging the FDA on the best path forward to approval.\u201d<\/p>\n\n\n\n

\u201cSpero is powered by incredibly hard-working and dedicated professionals who have made significant strides over the past year to bring the medicines in our pipeline forward and closer to patients. I would like to offer my heartfelt thanks to all our employees, especially those affected by today\u2019s announcement, for their contributions to Spero. We are committed to treating all impacted team members with fairness and respect, consistent with our culture, and to supporting them through this transition,\u201d concluded Dr. Mahadevia.<\/p>\n\n\n\n

Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP), Fast Track and Priority Review designations for treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date for June 27, 2022. On March 31, 2022, Spero announced that as part of the FDA\u2019s ongoing review of Spero\u2019s NDA for tebipenem HBr, the FDA had identified deficiencies that precluded the discussion of labeling and post-marketing requirements\/commitments at such time. Spero\u2019s LCM with the FDA was in late April 2022.<\/p>\n\n\n\n

In evaluating the efficacy of tebipenem HBr in the Phase 3 (ADAPT-PO) cUTI study, the FDA conducted a separate analysis of the microbiological intent-to-treat (micro-ITT) population, relative to the prespecified analysis as set forth in the previously submitted and reviewed protocol and statistical analysis plan for ADAPT-PO. The effect of this new analysis was to reduce the number of evaluable patients in the primary analysis population compared with those resulting from the trial\u2019s pre-specified micro-ITT population as outlined in the statistical analysis plan. As a result, the FDA considers that the pre-specified non-inferiority (NI) margin of -12.5% was not met.   Spero is continuing its dialogue with the FDA, as the company seeks a pathway forward for potential approval of tebipenem HBr.<\/p>\n\n\n\n

On April 7, 2022, The New England Journal of Medicine<\/em> published the results from the Phase 3 ADAPT-PO clinical trial, whose topline results Spero originally reported in September 2020. The article, titled \u201cOral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,\u201d is available online at The New England Journal of Medicine<\/a> (NEJM). <\/p>\n\n\n\n

Restructuring to Prioritize Programs and Capital Allocation<\/strong><\/p>\n\n\n\n

Spero ended the fourth quarter and year ended December 31, 2021 with an estimated $146.4 million in cash. Based on the restructuring and the cessation of commercialization activities for the tebipenem HBr program and assuming the repayment of amounts under the Company\u2019s Revenue Interest Financing Agreement with certain entities managed by HealthCare Royalty Management, LLC, Spero believes that its existing cash, cash equivalents and marketable securities, together with other non-dilutive funding commitments, will be sufficient to fund its planned operating expenses and capital expenditures pursuant to the priorities of its strategic refocusing through late 2023. During this period, the strategic refocusing prioritizes advancing SPR720 and SPR206 to Phase 2 milestones and includes key deliverables through 2024.<\/p>\n\n\n\n

Conference Call and Webcast<\/strong>
In connection with this announcement, Spero will host a conference call and webcast today at 8:30 a.m. ET. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13729673. The conference call will also be webcast live and a link to the webcast can be accessed here<\/a> and also on Spero Therapeutics’ website at <\/strong>www.sperotherapeutics.com<\/em><\/strong><\/a> in the “Investors and Media” section under “Events and Presentations.” An archived webcast will be available on Spero’s website for 30 days following the presentation. <\/p>\n\n\n\n

For more information, visit https:\/\/sperotherapeutics.com<\/em><\/strong><\/a>.<\/p>\n\n\n\n

Tebipenem HBr Research Support<\/strong>
The tebipenem HBr development program has been funded in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.<\/p>\n\n\n\n

About Spero<\/strong> Therapeutics<\/strong>
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multidrug resistant bacterial infections and rare diseases.<\/p>\n\n\n\n